JeniVision Overview

  • Founded
  • 2014
Founded
  • Status
  • Private
  • Latest Deal Type
  • Angel
  • Latest Deal Amount
  • $386K
Latest Deal Amount
  • Investors
  • 1

JeniVision General Information

Description

Owner and operator of a biopharmaceutical company intended to offer advanced therapies. The company's therapies are developed for treating ocular disease and skin problem, enabling patients to get their disease treated easily and effectively.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Angel-Backed
Primary Industry
Biotechnology
Other Industries
Pharmaceuticals
Drug Discovery
Primary Office
  • 5151 California Avenue
  • Suite 100
  • Irvine, CA 92617
  • United States
+1 (949) 000-0000
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

JeniVision Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Angel (individual) 21-Sep-2018 $386K 00000 Completed Startup
1. Accelerator/Incubator Completed Startup
To view JeniVision’s complete valuation and funding history, request access »

JeniVision Executive Team (2)

Name Title Board Seat Contact Info
Weizhen Wang Ph.D Co-Founder, Chief Executive Officer, Chief Financial Officer & Board Member
David Woodward Ph.D Co-Founder, Chief Technology Officer & Board Member
To view JeniVision’s complete executive team members history, request access »

JeniVision Board Members (2)

Name Representing Role Since
David Woodward Ph.D JeniVision Co-Founder, Chief Technology Officer & Board Member 000 0000
Weizhen Wang Ph.D JeniVision Co-Founder, Chief Executive Officer, Chief Financial Officer & Board Member 000 0000
To view JeniVision’s complete board members history, request access »

JeniVision Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
UCI Applied Innovation Accelerator/Incubator Minority 000 0000 000000 0
To view JeniVision’s complete investors history, request access »